Product image of Natpar (Parathyroid Hormone) supplied by GNH India

Natpar

Active Ingredient:
Parathyroid Hormone
Origin:
EU

Natpar (Parathyroid Hormone)

Parathyroid hormone (1-84), the active ingredient in Natpar, is a parathyroid hormone analog presented as a subcutaneous injectable for subcutaneous use. It is indicated for the treatment of hypoparathyroidism, helping to restore normal serum calcium levels in affected patients.

GNH India supplies Natpar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Clients benefit from consistent product availability and regulatory support across multiple regions.

Manufacturer / TM Owner

Takeda Pharmaceuticals International Ag Ireland Branch

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Natpar, a parathyroid hormone analog, is used to manage disorders of calcium metabolism associated with hypoparathyroidism.

  • Hypoparathyroidism: raises and maintains serum calcium levels in patients with chronic disease.
  • Post‑surgical hypoparathyroidism: supports calcium homeostasis after thyroid or parathyroid gland surgery.
  • Chronic hypoparathyroidism: provides long‑term regulation of calcium balance when endogenous PTH is deficient.

How It Works

  • Parathyroid hormone (1‑84) binds to PTH1 receptors on osteoblasts, renal tubular cells and the intestine, activating adenylate cyclase and phospholipase C pathways. This stimulates bone resorption, enhances renal calcium reabsorption, and promotes conversion of 25‑hydroxyvitamin D to its active form, collectively increasing serum calcium concentrations. The hormone also modulates phosphate handling by reducing renal phosphate reabsorption, contributing to mineral homeostasis.

Side Effects

Parathyroid hormone therapy may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Nausea: mild gastrointestinal upset.
  • Injection site reactions: redness, swelling or pain.
  • Hypercalcemia: mild elevation of serum calcium.

Serious or Rare Side Effects

  • Severe hypercalcemia: may lead to cardiac arrhythmia or renal dysfunction.
  • Osteosarcoma: theoretical risk based on animal data.
  • Anaphylaxis: rare allergic reaction requiring emergency care.

Precautions & Warnings

When using Natpar, several precautions should be observed to ensure safety and therapeutic effectiveness.

  • Monitor serum calcium: regular laboratory testing to avoid hypercalcemia.
  • Assess vitamin D status: ensure adequate levels before initiating therapy.
  • Adjust dose in renal impairment: reduced clearance may increase calcium levels.
  • Avoid use in existing hypercalcemia: contraindicated when calcium is already elevated.
  • Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Parathyroid hormone can interact with other agents that affect calcium balance or bone metabolism.

Major Interactions (Avoid)

  • Calcium supplements: may cause excessive hypercalcemia.
  • Active vitamin D analogs (calcitriol, alfacalcidol): additive increase in calcium levels.
  • Thiazide diuretics: enhance renal calcium reabsorption, raising risk of hypercalcemia.

Moderate Interactions (Monitor Closely)

  • Loop diuretics: may alter calcium excretion, requiring dose adjustment.
  • Bisphosphonates: opposite effect on bone turnover, may reduce efficacy.
  • Magnesium supplements: high levels can interfere with PTH activity.

Frequently Asked Questions

Natpar is a prescription injectable containing parathyroid hormone (1‑84) that is used to treat hypoparathyroidism. By replacing deficient endogenous hormone, it helps normalize serum calcium levels in patients whose parathyroid glands are unable to produce adequate hormone.

Parathyroid hormone binds to PTH1 receptors on bone, kidney and intestinal cells, activating signaling pathways that increase bone resorption, enhance renal calcium reabsorption, and stimulate conversion of vitamin D to its active form. These actions collectively raise blood calcium concentrations.

The dose of Natpar is individualized by the prescribing clinician based on the patient’s serum calcium, vitamin D status, renal function and clinical response. Dosage adjustments are made through regular monitoring rather than a fixed regimen.

Safety of Natpar in pregnancy and lactation has not been established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Natpar, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Natpar provides direct replacement of the missing hormone, whereas alternative therapies such as calcium supplements and active vitamin D analogs only address downstream effects. Hormone replacement can achieve more physiologic calcium regulation, but it requires injection and careful monitoring for hypercalcemia.

Natpar must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not store at ambient temperature for extended periods.

Natpar is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a qualified healthcare professional or a trained patient following aseptic technique. The exact injection schedule is determined by the prescribing clinician.

The most serious risks include severe hypercalcemia, which can lead to cardiac arrhythmias or renal impairment, and the theoretical risk of osteosarcoma observed in long‑term animal studies. Immediate medical attention is required if symptoms of severe hypercalcemia or an allergic reaction occur.

Natpar is contraindicated in patients with existing hypercalcemia, uncontrolled renal disease, or known hypersensitivity to parathyroid hormone preparations. Caution is also advised for individuals with a history of malignancy involving bone, due to the theoretical osteosarcoma risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Parathyroid Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT